Apothecary Pharma GLP-1 Injection Recall, All 22 Tirzepatide Lots and the NAD+ Vial
Apothecary Pharma LLC is recalling 23 vials of compounded injectable drugs nationwide because it cannot assure their sterility. The recall covers 22 vials of compounded tirzepatide injection and one vial of NAD+ injection. The company started the voluntary recall on September 24, 2026, and the FDA classified it as Class II on October 8, 2026….
